PLC
WHWK

Peapod Lane Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Peapod Lane Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-303,585
Closed -$577K – 61
2025
Q3 		$577K Buy
303,585
+61,375
+25% +$113K 0.52% 55
2025
Q2 		$453K Buy
242,210
+807
+0.3% +$1.41K 0.45% 56
2025
Q1 		$430K Sell
241,403
-201,539
-46% -$526K 0.48% 57
2024
Q4 		$1.4M Buy
+442,942
New +$1M 1.39% 32

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Peapod Lane Capital's WHWK Position: Q4 2025 in Review

Peapod Lane Capital sold out of Whitehawk Therapeutics (WHWK) in Q4 2025, closing a stake of 303,585 shares — an estimated $577K sold.

Peapod Lane Capital first reported a position in WHWK in Q4 2024 and held it in 4 quarters. The position peaked at $1.4M in Q4 2024. 48 funds tracked by Wall St. Rank hold WHWK as of Q4 2025.

  • Peapod Lane Capital reported no remaining Whitehawk Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Peapod Lane Capital sold 303,585 Whitehawk Therapeutics shares in Q4 2025, an estimated $577K.
  • Peapod Lane Capital first reported a position in Whitehawk Therapeutics in Q4 2024 and held it in 4 quarters.
  • Peapod Lane Capital's Whitehawk Therapeutics position peaked at $1.4M in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2025.

Based on Peapod Lane Capital's 13F filing for Q4 2025, filed 28 Jan 2026.